Kodiak(KOD) Prnewswire·2025-02-04 12:30Core Insights - Kodiak Sciences Inc. is presenting its glaucoma treatment pipeline at the Glaucoma 360 New Horizons Forum 2025, focusing on a dual-acting therapy that targets neuroinflammation and intraocular pressure [1][3][5] Company Overview - Kodiak Sciences is a biopharmaceutical company dedicated to developing transformative therapeutics for retinal diseases, utilizing its Antibody Biopolymer Conjugate Drug (ABCD) platform [6][11] - The company is advancing three clinical programs, with two in late-stage development and one expected to progress rapidly into pivotal studies [6] Industry Context - Glaucoma is the leading cause of irreversible blindness, affecting around 76 million people globally, with current therapies primarily focused on lowering intraocular pressure [2] - Emerging research highlights neuroinflammation as a significant factor in optic neuropathy associated with glaucoma [2] Product Development - Kodiak's investigational "duet" therapy aims to reduce neuroinflammation and lower intraocular pressure, potentially transforming glaucoma treatment [3][4] - The therapy targets the NLRP3 inflammasome and is designed for quarterly dosing, offering a comprehensive solution to slow disease progression [3][4] Clinical Trials - Kodiak's lead investigational medicine, tarcocimab, is undergoing two Phase 3 clinical trials for diabetic retinopathy and wet AMD, actively enrolling patients [7] - KSI-501, another investigational medicine, is designed to inhibit IL-6 mediated inflammation and is also in a Phase 3 study for wet AMD [8][9] - KSI-101 is being developed for retinal inflammatory diseases, with a Phase 1b study currently enrolling patients [10]